NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2024 – Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 2, 2024 – Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical utility to optimize treatment selection. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – November 25, 2024 – Agendia®, Inc., announced today that new data on its Read More
Newsroom
News, Stories & Breast Cancer Blog
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the Article









